Chardan Capital Maintains Buy on Prothena Corp, Maintains $40 Price Target

Benzinga · 6d ago
Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $40 price target.